相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。NFκB signaling is important for growth of antiestrogen resistant breast cancer cells
Christina W. Yde et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers
Rita Nahta et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells
S. Cutrupi et al.
ONCOGENE (2012)
Mechanisms of Endocrine Resistance in Breast Cancer
C. Kent Osborne et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
C. Davies et al.
LANCET (2011)
Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance
Katrine Sonne-Hansen et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
New Strategies in Estrogen Receptor-Positive Breast Cancer
Stephen R. D. Johnston
CLINICAL CANCER RESEARCH (2010)
Deconstructing repression: evolving models of co-repressor action
Valentina Perissi et al.
NATURE REVIEWS GENETICS (2010)
Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant
Thomas Frogne et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Biological determinants of endocrine resistance in breast cancer
Elizabeth A. Musgrove et al.
NATURE REVIEWS CANCER (2009)
Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors
Thomas Frogne et al.
BREAST CANCER RESEARCH (2009)
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
Birgitte B. Rasmussen et al.
LANCET ONCOLOGY (2008)
Endocrine therapy - current benefits and limitations
RI Nicholson et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients
AA Memon et al.
BRITISH JOURNAL OF CANCER (2004)
Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells
IR Hutcheson et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells
JM Knowlden et al.
ENDOCRINOLOGY (2003)
Endocrine-responsive breast cancer and strategies for combating resistance
S Ali et al.
NATURE REVIEWS CANCER (2002)
Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways
BK Lundholt et al.
BREAST CANCER RESEARCH AND TREATMENT (2001)
分享论文
